KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability (2017 - 2018)

Amneal Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $1.2 million for Q4 2018.

  • Quarterly results put Non-Current Deferred Tax Liability at $1.2 million for Q4 2018, down 52.71% from a year ago — trailing twelve months through Dec 2018 was $1.2 million (down 52.71% YoY), and the annual figure for FY2018 was $1.2 million, down 52.71%.
  • Non-Current Deferred Tax Liability for Q4 2018 was $1.2 million at Amneal Pharmaceuticals, down from $1.8 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for AMRX hit a ceiling of $2.5 million in Q4 2017 and a floor of $1.2 million in Q4 2018.